Product Code: ETC8854049 | Publication Date: Sep 2024 | Updated Date: Jun 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Closely related to the general vasomotor symptoms market, the VMS treatment market focuses on menopausal patients. The use of hormonal therapy, SSRIs, and herbal remedies like black cohosh and soy isoflavones is becoming more common. Increased educational campaigns and womens wellness programs are helping reduce stigma around menopause and supporting market development.
A sub-segment of the broader menopausal treatment space, the VMS treatment market is growing as women seek relief from quality-of-life-disrupting symptoms. While HRT dominates prescriptions, theres a growing shift toward plant-based and bioidentical hormone treatments. Educational initiatives by OB-GYNs and wellness clinics are playing a role in encouraging early intervention, especially among urban and middle-income populations.
Beyond cultural barriers, the VMS treatment market faces gaps in patient education and a lack of trained gynecologists outside urban areas. Accessibility to hormone and non-hormone therapies is still limited by supply constraints and high treatment costs.
This subset of the menopausal treatment segment offers further potential, particularly in non-hormonal pharmaceuticals and herbal therapies. Brands offering natural or prescription VMS treatments could capture market share by collaborating with OB-GYN networks, leveraging digital marketing, and supplying wellness clinics focused on midlife women.
The DOH promotes awareness and health interventions for menopausal women, although VMS-specific programs are minimal. Treatments like hormone replacement therapies are FDA-regulated and available via prescription. Government clinics offer limited options through womens health services.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market - Industry Life Cycle |
3.4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market - Porter's Five Forces |
3.5 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.7 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.8 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends |
6 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Types |
6.1 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Antidepressants, 2021- 2031F |
6.1.4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Fluoxetine, 2021- 2031F |
6.1.5 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Paroxetine, 2021- 2031F |
6.1.6 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Sertraline, 2021- 2031F |
6.1.7 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Hormone Therapy, 2021- 2031F |
6.1.8 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Anticonvulsant, 2021- 2031F |
6.1.9 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Phenobarbital, 2021- 2031F |
6.1.10 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Phenobarbital, 2021- 2031F |
6.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Route of Administration |
6.2.1 Overview and Analysis |
6.2.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Oral, 2021- 2031F |
6.2.3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.2.4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market, By End-Users |
6.3.1 Overview and Analysis |
6.3.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.3.4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Homecare, 2021- 2031F |
6.3.5 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.4.3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.4.4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.4.5 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Others, 2021- 2031F |
7 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Import-Export Trade Statistics |
7.1 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Export to Major Countries |
7.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Imports from Major Countries |
8 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Key Performance Indicators |
9 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market - Opportunity Assessment |
9.1 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market - Competitive Landscape |
10.1 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenue Share, By Companies, 2024 |
10.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |